Blog

Designing better medicines using AI and big data

By its own definition, South By Southwest dedicates itself to helping creatives achieve their goals, and proves that the most unexpected discoveries happen when diverse topics and people come together.

And this is what brought our Benevolent Team to Texas - to share our collective vision of using the power of technology to solve something that truly matters to the world. For us this means tackling the most challenging and devastating diseases that currently have no cure, and we believe our efforts can and will change outcomes for patients.

In this video live from SXSW last month, our team of scientists and AI experts presented a ‘behind the scenes’ introduction to show how our latest advancements in machine learning and AI can better understand the underlying causes of diseases, and redefine the way in which new medicines are discovered and brought to patients.

At SXSW we used the example of Glioblastoma Multiforme, a very aggressive, currently incurable and most common form of brain cancer. We demonstrated something different and a little unconventional - the creative approach of how our team of BenevolentAI scientists, AI experts, engineers and chemists come together to try and solve such a complicated disease.

AI helps us uncover relationships between diseases and symptoms, drugs and their effect, the patients who respond to treatments and so much more. Relationships that would previously not have been uncovered due to the overwhelming volume of biomedical information and the inherent complexity of biology, diseases and the human body.

It’s too early to say if there will be an effective treatment for Glioblastoma any time soon. But every day, we improve our platform and increase the likelihood of finding a treatment. And we hope to return to SXSW to demonstrate the progress we are making on this devastating disease.

More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021